Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: Clin Cancer Res. 2015 Jun 18;21(20):4642–4651. doi: 10.1158/1078-0432.CCR-15-0781

Figure 6.

Figure 6

Reversibility of the ibrutinib-induced adhesion defect. A, Cells obtained from patients pre-treatment (Pre) or on ibrutinib were left unstimulated or stimulated with PMA for 1 hour. Shown is the mean (± SEM) percent reduction in adhesion normalized to pre-treatment samples (n=12). B, Adhesion of CLL PBMCs sampled during ibrutinib treatment analyzed under four different treatment conditions; cells were left unstimulated or stimulated with PMA, and in each of these two conditions cells were incubated with or without the addition of firategrast (FIR; VLA-4 antagonist). Data is normalized to cells without PMA and without FIR, representing the effect of ibrutinib (IB) in vivo. Shown is the mean (± SEM) percent change in cell adhesion (n=11). All P values were determined by a Wilcoxon matched pairs test.